SPAC1639.01c Antibody

What is SPAC1639.01c and why is it significant for research?

SPAC1639.01c is a gene in Schizosaccharomyces pombe (fission yeast) that encodes a putative elongation of fatty acids protein 2 (also known as 3-keto acyl-CoA synthase or very-long-chain 3-oxoacyl-CoA synthase 2) . This protein belongs to the GNS1/SUR4 family and plays a crucial role in fatty acid metabolism. It is significant for research because:

• It serves as a model for studying fatty acid elongation mechanisms

• It provides insights into lipid metabolism pathways conserved across species

• It helps in understanding cell membrane composition regulation

• It can be used to investigate metabolic disorders related to fatty acid synthesis

The enzyme (EC 2.3.1.199) catalyzes key reactions in the fatty acid elongation cycle, making it valuable for studying lipid biosynthesis at the molecular level .

What are the best applications for polyclonal versus monoclonal SPAC1639.01c antibodies?

While both polyclonal and monoclonal SPAC1639.01c antibodies have their uses in research, their optimal applications differ based on experimental requirements:

For experiments requiring detection of native SPAC1639.01c in yeast lysates, polyclonal antibodies often provide better sensitivity, while monoclonal antibodies excel in applications requiring consistent results across multiple experiments .

What validation methods should be used to confirm SPAC1639.01c antibody specificity?

Ensuring antibody specificity is critical for obtaining reliable research results. For SPAC1639.01c antibodies, the following validation methods are recommended:

• Western Blot Analysis: Run parallel blots with wildtype and SPAC1639.01c knockout S. pombe lysates to confirm detection of a band at the expected molecular weight (~33 kDa) that is absent in the knockout

• Immunoprecipitation-Mass Spectrometry: Confirm that the immunoprecipitated protein is indeed SPAC1639.01c by mass spectrometry analysis, similar to the approach used for SpA5 antibody validation

• Peptide Competition Assay: Pre-incubate the antibody with purified SPAC1639.01c peptide before immunostaining to verify signal reduction

• Overexpression Controls: Compare signal between normal and SPAC1639.01c-overexpressing cells

• Cross-Reactivity Testing: Test antibody against related proteins (e.g., other GNS1/SUR4 family members) to ensure specificity

A comprehensive validation approach combines at least three of these methods to ensure robust specificity before proceeding with experimental applications.

What optimization steps are necessary for Western blotting with SPAC1639.01c antibodies?

Optimizing Western blotting conditions for SPAC1639.01c antibodies involves several critical steps:

• Sample Preparation:

  • Use fresh S. pombe cultures harvested in mid-log phase

  • Include protease inhibitors in lysis buffer to prevent degradation

  • Consider membrane fractionation techniques as SPAC1639.01c is membrane-associated

• Antibody Dilution Optimization:

  • Test serial dilutions (1:500, 1:1000, 1:2000, 1:5000) of primary antibody

  • Optimal dilution for rabbit polyclonal anti-SPAC1639.01c is typically 1:1000 for standard detection systems

• Blocking Conditions:

  • 5% BSA in TBST is often more effective than milk-based blockers for fatty acid metabolism proteins

  • Extend blocking time to 2 hours at room temperature to reduce background

• Detection System Selection:

  • Chemiluminescence provides better sensitivity for low-abundance targets

  • Consider fluorescent secondary antibodies for quantitative analysis

• Controls:

  • Include positive control (purified recombinant SPAC1639.01c)

  • Run negative control (SPAC1639.01c knockout strain)

  • Consider loading control (e.g., actin) for normalization

The optimization process should be methodically documented to ensure reproducibility across experiments and laboratory personnel.

How can computational modeling enhance epitope prediction for designing improved SPAC1639.01c antibodies?

Computational approaches can significantly enhance the design of SPAC1639.01c antibodies by predicting optimal epitopes and improving binding affinity:

• Structure Prediction and Molecular Docking:
  Using protocols like IsAb, researchers can predict the 3D structure of SPAC1639.01c and potential antibody-antigen complexes . The process involves:

  • Generating 3D structure using RosettaAntibody if no structural data is available

  • Performing two-step docking with ClusPro for global docking followed by SnugDock for local docking

  • Identifying binding poses and interface residues

• Epitope Mapping through In Silico Alanine Scanning:
  This computational technique can predict hotspots on SPAC1639.01c by:

  • Mutating interface residues to alanine

  • Calculating energy changes during mutation

  • Identifying residues critical for antibody binding

• Affinity Maturation Simulation:
  Using Rosetta-based protocols, researchers can:

  • Generate mutations in complementarity-determining regions (CDRs)

  • Evaluate binding energy changes

  • Select mutations predicted to improve affinity and stability

• Validation of Computational Predictions:
  As demonstrated with other antibodies like Abs-9 , predicted epitopes can be validated by:

  • Synthesizing predicted epitope peptides (e.g., coupling to KLH)

  • Testing binding affinity by ELISA

  • Performing competitive binding assays

For SPAC1639.01c specifically, computational modeling might identify immunogenic regions within the catalytic domain that could serve as optimal targets for antibody development, potentially improving specificity and reducing cross-reactivity with other GNS1/SUR4 family proteins.

What approaches resolve discrepancies in SPAC1639.01c localization between immunofluorescence and subcellular fractionation studies?

Researchers often encounter contradictory results between different localization techniques when studying SPAC1639.01c. To resolve these discrepancies:

• Comprehensive Methodological Comparison:

• Integrative Approach to Reconcile Discrepancies:

  • Perform correlative light and electron microscopy (CLEM)

  • Use proximity labeling techniques (BioID or APEX)

  • Employ super-resolution microscopy to increase spatial precision

• Control Experiments:

  • Generate tagged versions of SPAC1639.01c with minimal functional interference

  • Validate antibody specificity in fixed cells using knockout controls

  • Compare localization patterns during different cell cycle stages and growth conditions

• Alternative Validation Methods:

  • Use orthogonal approaches like mass spectrometry of purified organelles

  • Employ functional assays to confirm biological activity at suspected locations

  • Perform co-localization studies with known compartment markers

By systematically implementing these approaches, researchers can distinguish between technical artifacts and genuine biological complexity in SPAC1639.01c localization patterns.

How can single-cell RNA and VDJ sequencing be adapted for antibody development against SPAC1639.01c?

The high-throughput approach used for developing Abs-9 against SpA5 can be adapted for SPAC1639.01c antibody development:

• Immunization Strategy Adaptation:

  • Immunize volunteers or model organisms with recombinant SPAC1639.01c

  • Design a vaccination schedule to maximize affinity maturation

  • Monitor serum antibody titers to identify optimal B cell collection timepoints

• B Cell Isolation and Sequencing:

  • Co-incubate peripheral blood lymphocytes with biotin-labeled SPAC1639.01c

  • Sort antigen-specific memory B cells using flow cytometry

  • Perform high-throughput single-cell RNA and VDJ sequencing on isolated cells

• Bioinformatic Analysis Pipeline:

  • Identify highly expressed clonal IgG sequences

  • Select TOP10 sequences based on expression levels and binding prediction

  • Construct phylogenetic trees of clonotypes to identify affinity-matured variants

• Expression and Characterization:

  • Clone heavy and light chain sequences into expression vectors

  • Express and purify recombinant antibodies

  • Test binding affinity using techniques like ELISA and Biolayer Interferometry

• Specificity Validation:

  • Perform mass spectrometry after immunoprecipitation to confirm target specificity

  • Test cross-reactivity with related proteins from the GNS1/SUR4 family

  • Validate antibody function in relevant biological assays

This approach can potentially identify antibodies with nanomolar affinity for SPAC1639.01c, similar to the Abs-9 antibody which demonstrated a KD value of 1.959 × 10⁻⁹ M for its target .

What methodologies can determine if post-translational modifications of SPAC1639.01c affect antibody recognition?

Post-translational modifications (PTMs) can significantly impact antibody recognition of SPAC1639.01c. To investigate this:

• Identification of Potential PTMs:

  • Perform mass spectrometry analysis of purified SPAC1639.01c

  • Use predictive algorithms to identify potential PTM sites

  • Compare PTM patterns across different growth conditions

• Generation of Modified and Unmodified Antigens:

  • Express recombinant SPAC1639.01c in systems with different PTM capabilities

  • Use site-directed mutagenesis to create PTM-mimicking or PTM-deficient variants

  • Synthesize peptides with and without specific modifications

• Differential Binding Analysis:

  • Test antibody binding to modified vs. unmodified proteins using:

    • ELISA with different antigen preparations

    • Surface Plasmon Resonance (SPR) for real-time binding kinetics

    • Western blotting under different denaturing conditions

• Epitope Mapping with PTM Focus:

  • Use hydrogen-deuterium exchange mass spectrometry (HDX-MS)

  • Perform peptide array analysis with modified and unmodified peptides

  • Apply computational docking simulations incorporating PTMs

• Development of PTM-Specific Antibodies:

  • Generate antibodies specifically targeting modified forms of SPAC1639.01c

  • Create a panel of antibodies recognizing different PTM states

  • Validate specificity using knockout and point mutation controls

Understanding the impact of PTMs on antibody recognition is crucial for experimental design and interpretation, particularly in studies investigating SPAC1639.01c regulation under different cellular conditions.

How can epitope mapping techniques be employed to develop antibodies that distinguish between SPAC1639.01c and related proteins in the GNS1/SUR4 family?

Developing highly specific antibodies that can distinguish SPAC1639.01c from related GNS1/SUR4 family members requires sophisticated epitope mapping approaches:

• Comparative Sequence Analysis:

  • Perform multiple sequence alignment of GNS1/SUR4 family proteins

  • Identify unique regions in SPAC1639.01c with low homology to related proteins

  • Calculate antigenicity scores for unique regions using prediction algorithms

• Structural Epitope Mapping:

  • Use the AlphaFold2 method to predict 3D structures of SPAC1639.01c and related proteins

  • Identify surface-exposed regions unique to SPAC1639.01c

  • Perform molecular docking to predict antibody binding sites

• Experimental Epitope Determination:

  • Use hydrogen-deuterium exchange mass spectrometry (HDX-MS)

  • Perform X-ray crystallography of antibody-antigen complexes

  • Apply peptide array technology with overlapping peptides

• Cross-Reactivity Testing:

  • Express recombinant versions of all GNS1/SUR4 family members

  • Test antibody binding against the entire protein panel

  • Perform competitive binding assays to assess specificity

• Epitope Validation and Refinement:

  • Create synthetic peptides based on predicted epitopes

  • Couple epitopes to carrier proteins like KLH for immunization

  • Test competitive binding between whole protein and epitope peptides

The methodology used for SpA5 epitope identification could be adapted here, where molecular docking predicted antigenic epitopes that were then validated through ELISA and competitive binding assays .

How can researchers integrate SPAC1639.01c antibody data with other omics approaches for comprehensive pathway analysis?

Integrating SPAC1639.01c antibody data with other omics approaches provides a more holistic understanding of fatty acid elongation pathways:

• Multi-omics Integration Strategy:

  • Combine antibody-based proteomics with transcriptomics to correlate protein and mRNA levels

  • Integrate metabolomics to track fatty acid intermediates and products

  • Include lipidomics to assess membrane composition changes

• Network Analysis Approach:

  • Map SPAC1639.01c interactions using antibody-based techniques (co-IP, proximity labeling)

  • Construct protein-protein interaction networks around SPAC1639.01c

  • Identify pathway connections through functional enrichment analysis

• Temporal and Spatial Resolution:

  • Use antibodies for time-course studies of SPAC1639.01c expression and localization

  • Correlate with dynamic transcriptome and metabolome changes

  • Develop computational models of pathway dynamics

• Functional Validation Methods:

  • Apply CRISPR interference/activation to modulate SPAC1639.01c levels

  • Use antibodies to track resultant changes in protein expression and localization

  • Correlate with metabolic flux analysis of fatty acid pathways

• Data Integration Platforms:

  • Implement machine learning approaches to identify patterns across omics datasets

  • Use systems biology modeling to predict pathway behavior

  • Develop visualization tools for multi-dimensional data integration